

Director's Share Dealings

February 21, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces it was notified on February 20, 2014 that on that day, Matthew Emmens, the Company's Chairman, sold 36,100 Ordinary Shares in the Company ("Shares") at an average sale price of £33.14853. The Shares were sold on the London Stock Exchange.

Following the above transaction, Mr Emmens holds 56,774 Shares and 5,872 American Depositary Shares in the Company ("ADSs"). Each ADS represents three Shares.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor Relations

Laurie Stelzer	lstelzer@shire.com	+1 858 754 5480
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com